Galantamine
As of the edition of 20 October 2026, Galantamine is a small molecule: marketed, first approved in 2000 (FR); acts on ACHE.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Small molecule
- Brand name
- Razadyne
- First approved
- 6 October 2000 (FR)
- Approvals on record
- 10 in 4 regions
- Holder of the most recent approval
- Johnson & Johnson; 4 holders in all
- Registered trials
- 79, 10 stopped early
- Disease areas
- Mental health; Nervous system; Heart and blood vessels; Nutrition and metabolism; Chemically induced; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Galantamine.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ACHE | Acetylcholinesterase | P22303 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 11 | 9 | 0 | 1 |
| Phase 1 | 8 | 6 | 1 | 1 |
| Phase 2 | 12 | 10 | 1 | 1 |
| Phase 3 | 27 | 23 | 2 | 2 |
| Phase 4 | 21 | 14 | 0 | 5 |
| All trials | 79 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Johnson & Johnson | Originator, Applicant, Later holder and Lead sponsor of trials | 1995 to now |